Novel agents and biomarkers for acute lymphoid leukemia

Zhao, Yanmin; Huang, He; Wei, Guoqing

doi:10.1186/1756-8722-6-40

Cited by 25 publications

(18 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T cell-acute lymphoblastic leukemia (T-ALL) is fatal in about 50-70% of adult patients [ 77 ]-[ 79 ]. SINE has shown striking activity in preclinical study for treatment of T-ALL.…”

Section: Sine In Acute Leukemiamentioning

confidence: 99%

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents

et al. 2014

View full text Add to dashboard Cite

Dysregulation of the nucleo-cytoplasmic transport of proteins plays an important role in carcinogenesis. The nuclear export of proteins depends on the activity of transport proteins, exportins. Exportins belong to the karyopherin β superfamily. Exportin-1 (XPO1), also known as chromosomal region maintenance 1 (CRM1), mediates transport of around 220 proteins. In this review, we summarized the development of a new class of antitumor drugs, collectively known as selective inhibitors of nuclear export (SINE). KPT-330 (selinexor) as an oral agent is showing activities in early clinical trials in both solid tumors and hematological malignancies.Electronic supplementary materialThe online version of this article (doi:10.1186/s13045-014-0078-0) contains supplementary material, which is available to authorized users.

show abstract

“…T cell-acute lymphoblastic leukemia (T-ALL) is fatal in about 50-70% of adult patients [ 77 ]-[ 79 ]. SINE has shown striking activity in preclinical study for treatment of T-ALL.…”

Section: Sine In Acute Leukemiamentioning

confidence: 99%

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents

et al. 2014

View full text Add to dashboard Cite

show abstract

“…El tratamiento de la leucemia linfoblástica aguda combina actualmente quimioterapia, inmunoterapia y blancos moleculares (1)(2)(3) . Uno de los esquemas más populares es el Hyper-CVAD (4) .…”

Section: Introductionunclassified

Comparación del hyper-CVAD con un régimen institucional en el tratamiento de la leucemia linfoblástica aguda del adulto en un hospital de México

Ramos-Peñafiel

Cabrera-García

Rozen-Fuller

et al. 2014

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

RESUMENCon el objetivo de evaluar la mortalidad y toxicidad del protocolo Hyper-CVAD utilizado como primera línea de tratamiento de la leucemia linfoblástica aguda se realizó un estudio de cohorte retrospectiva en pacientes de 40 años a menos durante marzo a septiembre de 2011 atendidos con el régimen Hyper-CVAD. La mortalidad y toxicidad se comparó con los resultados de los pacientes atendidos con el régimen institucional HGMLAL07 entre 2009 a 2012. Se incluyeron 18 pacientes, la mediana de edad fue de 26 años. Tanto las remisiones completas (67,7% frente a 81,9%) como la supervivencia a un año (40% frente a 62%) y 2 años (18% frente a 34%) fueron menores con el régimen Hyper-CVAD. Al seleccionar exclusivamente pacientes menores de 35 años, la eficacia de Hyper-CVAD también fue menor. Según esta experiencia y debido a su alto costo y toxicidad, el régimen Hyper-CVAD debe de limitarse a aquellos pacientes con leucemias refractarias o en recaída. Palabras clave: Leucemia linfoblástica; Protocolos de quimioterapia combinada antineoplásica; Adulto (fuente DeCS BIREME). COMPARISON OF THE HYPER-CVAD WITH AN INSTITUTIONAL REGIMEN FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS IN A HOSPITAL OF MEXICO ABSTRACTIn order to assess the mortality and toxicity of the Hyper-CVAD protocol used as first-line treatment of acute lymphoblastic leukemia, a retrospective cohort study was performed in patients less than 40 years of age from March to September 2011 treated with Hyper-CVAD regimen. Mortality and toxicity was compared with the results of patients treated with the institutional HGMLAL07 regimen between 2009-2012. 18 patients were included; the median age was 26 years old. Complete remissions (67.7% versus 81.9%) as well as one-year (40% versus 62%) and 2 year survival rates (18% versus 34%) were lower with the Hyper-CVAD regimen. By selecting only patients younger than 35 years, the effectiveness of Hyper-CVAD was also lower. In our experience and because of its high cost and toxicity, the Hyper-CVAD regimen should be limited to patients with relapsed or refractory leukemia.

show abstract

“…In the past, the classic prognostic factors were age, presenting white blood cell (WBC) counts, cytogenetic abnormalities and upfront response to induction therapy. One of the strongest adverse prognostic features is the presence of the Philadelphia chromosome t (9; 22) [2]. Although more than 80% of adult patients with Philadelphia chromosome (Ph)-negative ALL achieve complete remission (CR) with conventional induction therapy, their 5-year survival is only 30% -40%.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and Prognostic Significance of Histidine-Rich Glycoprotein in Acute Lymphoblastic Leukemia

Ahmed¹,

Almogbel²,

Khirry³

et al. 2017

OJBD

View full text Add to dashboard Cite

Background: Histidine-rich glycoprotein (HRG), a multifunctional plasma protein, has a regulatory role in homeostasis, angiogenesis, and immunity; which in turn could greatly affect tumor control and metastasis. Objectives: To assess the possible role of HRG in acute lymphoblastic leukemia (ALL) tumorgenesis and follow-up. Design and Methods: HRG was quantitatively measured in serum by ELISA and its expression was assessed by real-time PCR (qPCR) in 35 patients with ALL and compared to same 25 ALL patients after induction therapy and 30 age and sex matched healthy control subjects. Results: HRG-serum protein (at cutoff value 63.55 pg/ml) and HRG-RNA (at cutoff value 0.955) were positive in all ALL patients before therapy, but in only 76% after therapy for HRG-protein and 60% for HRG-RNA and they could not be detected in the control group; P < 0.001. Additionally, the serum HRG level showed a significant positive correlation with its expression level, bone marrow blast percentage, peripheral blood blast count, P < 0.01. Also its serum and expression levels were positively related to the poor risk Philadelphia chromosome; P < 0.01. Conclusions: HRG (protein and RNA) might be considered as a novel diagnostic and prognostic marker in ALL. HRG-serum protein level, detected by simple methodology of ELISA, has more significant advantages than its expression level, motivating its application in large clinical studies as a potential marker.

show abstract

Novel agents and biomarkers for acute lymphoid leukemia

Cited by 25 publications

References 65 publications

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents

Comparación del hyper-CVAD con un régimen institucional en el tratamiento de la leucemia linfoblástica aguda del adulto en un hospital de México

Diagnostic and Prognostic Significance of Histidine-Rich Glycoprotein in Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About